The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5).


Journal

Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645

Informations de publication

Date de publication:
02 2021
Historique:
received: 31 08 2020
revised: 06 11 2020
accepted: 11 11 2020
pubmed: 18 11 2020
medline: 6 7 2021
entrez: 17 11 2020
Statut: ppublish

Résumé

To identify responders to continuous glucose monitoring (CGM) in relation to reductions in HbA1c and percentage of time spent in hypoglycaemia after initiation of CGM for individuals with type 1 diabetes treated with multiple daily insulin injections. We analysed data from 142 participants in the GOLD randomized clinical trial. We evaluated how many lowered their HbA1c by more than 0.4% (>4.7 mmol/mol) or decreased the time spent in hypoglycaemia over 24 hours by more than 20 or 30 minutes, and which baseline variables were associated with those improvements. Lower reduction of HbA1c was associated with greater reduction of hypoglycaemia (r = -0.52; P < .0001). During CGM, 47% of participants lowered their HbA1c values by more than 0.4% (>4.7 mmol/mol) than with self-measurement of blood glucose, and 47% decreased the time spent in hypoglycaemia by more than 20 minutes over 24 hours. Overall, 78% either reduced their HbA1c by more than 0.4% (>4.7 mmol/mol) or the time spent in hypoglycaemia by more than 20 minutes over 24 hours, but only 14% improved both. Higher HbA1c, a lower percentage of time at less than 3.0 or 3.9 mmol/L, a lower coefficient of variation (CV) and a higher percentage of time above 13.9 mmol/L (P = .016) were associated with greater HbA1c reduction during CGM. The variables associated with a greater reduction of time in hypoglycaemia were female sex, greater time with glucose levels at less than 3.0 mmol/L, higher CV, and higher hypoglycaemia confidence as evaluated by a hypoglycaemic confidence questionnaire. The majority of people with type 1 diabetes managed by multiple daily insulin injections benefit from CGM; some experienced reduced HbA1c while others reduced the time spent in hypoglycaemia. These factors need to be considered by healthcare professionals and decision-makers for reimbursement and diabetes guidelines.

Identifiants

pubmed: 33200487
doi: 10.1111/dom.14257
pmc: PMC7839699
doi:

Substances chimiques

Blood Glucose 0
Glycated Hemoglobin A 0
Hypoglycemic Agents 0
Insulin 0

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

619-630

Informations de copyright

© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Références

Diabetes Metab Res Rev. 2008 Feb;24(2):87-92
pubmed: 18088077
Diabetes Care. 2009 Nov;32(11):1947-53
pubmed: 19675206
Diabetes Obes Metab. 2021 Feb;23(2):619-630
pubmed: 33200487
JAMA. 2017 Jan 24;317(4):371-378
pubmed: 28118453
Diabetes Technol Ther. 2018 Aug;20(8):561-565
pubmed: 30044123
Diabetes Technol Ther. 2018 Apr;20(4):274-284
pubmed: 29608107
J Diabetes Sci Technol. 2016 May 03;10(3):754-61
pubmed: 27081191
Semin Clin Neuropsychiatry. 1997 Jan;2(1):57-65
pubmed: 10320443
Diabet Med. 2010 Sep;27(9):1060-5
pubmed: 20722681
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Clin Chem Lab Med. 2002 Jan;40(1):78-89
pubmed: 11916276
N Engl J Med. 2019 Oct 31;381(18):1707-1717
pubmed: 31618560
N Engl J Med. 2005 Dec 22;353(25):2643-53
pubmed: 16371630
Diabetologia. 2012 Dec;55(12):3155-62
pubmed: 22965294
N Engl J Med. 2005 Jan 13;352(2):174-83
pubmed: 15647580
Endocrinol Metab Clin North Am. 2010 Sep;39(3):641-54
pubmed: 20723825
N Engl J Med. 2014 Nov 20;371(21):1972-82
pubmed: 25409370
Diabetes Technol Ther. 2019 Jan;21(1):1-5
pubmed: 30575408
J Diabetes Sci Technol. 2019 Jul;13(4):636-644
pubmed: 30841740
BMJ. 2019 Aug 28;366:l4894
pubmed: 31462492
JAMA. 2017 Jan 24;317(4):379-387
pubmed: 28118454
Diabetes Care. 2011 May;34 Suppl 2:S132-7
pubmed: 21525444
Diabetes Care. 2016 Aug;39(8):1378-83
pubmed: 27411699
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
N Engl J Med. 2013 Jul 25;369(4):362-72
pubmed: 23883381

Auteurs

Arndís F Ólafsdóttir (AF)

Department of Medicine, NU-Hospital Group, Uddevalla, Sweden.
Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.

Jan Bolinder (J)

Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.

William Polonsky (W)

Behavioral Diabetes Institute, San Diego, Californa.
Department of Medicine, University of California, San Diego, California.

Magnus Ekelund (M)

Department of Clinical Sciences, Lund University, Lund, Sweden.

Magnus Wijkman (M)

Department of Internal Medicine and Department of Health, Medicine and Caring Sciences, Linköping University, Norrköping, Sweden.

Aldina Pivodic (A)

Statistiska Konsultgruppen, Gothenburg, Sweden.
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Elsa Ahlén (E)

Department of Medicine, NU-Hospital Group, Uddevalla, Sweden.
Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.

Erik Schwarcz (E)

Department of Internal Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Thomas Nyström (T)

Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.

Jarl Hellman (J)

Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.

Irl B Hirsch (IB)

School of Medicine, University of Washington, Seattle, Washington.

Marcus Lind (M)

Department of Medicine, NU-Hospital Group, Uddevalla, Sweden.
Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH